Newstral
Article
Mmarketwatch.com on 2017-04-26 23:32
Neurocrine Biosciences’ new drug may cost patients more than $10,000 a month, twice as much as expected
Related news
- MNeurocrine Biosciences says trial of Tourette syndrome treatment missed primary goalmarketwatch.com
- Neurocrine: Q4 Earnings SnapshotThe Fresno Bee
- Neurocrine: Q2 Earnings SnapshotMerced Sun-Star
- Neurocrine: Q1 Earnings SnapshotMerced Sun-Star
- MNeurocrine stock rockets to a record on sales beat—but can it last?marketwatch.com
- NNewspapers cost more than twice as much today as they did a decade ago (and that was a smart move by publishers)niemanlab.org
- West Boca teacher wins $10,000 for invention for respiratory patientsSun Sentinel
- Apple unveils headphones that cost twice as much as AirPodsSydney Morning Herald
- HGerman Subs to Cost Twice as Much as Plannedhamodia.com
- Cancer patients are twice as likely to declare bankruptcyChicago Tribune
- FWaits twice as long for some local patientsfermanaghherald.com
- MSolid Biosciences shares plunge as FDA puts study on clinical holdmarketwatch.com
- Precision BioSciences: Q3 Earnings SnapshotMerced Sun-Star
- Precision BioSciences: Q1 Earnings Snapshotsanluisobispo.com